Ketamine Tablet as Antidepressant Augmentation

Ketamine's glutamatergic mechanism is fundamentally distinct from conventional antidepressants, making it a logical candidate for combination therapy — addressing treatment-resistant depression through complementary mechanisms. In practice, ketamine tablet is almost always prescribed alongside existing antidepressants rather than as monotherapy. Understanding the rationale, evidence, and practical considerations for this combination approach is essential for patients and prescribers.

The Case for Combination Therapy

Mechanistic Complementarity

Conventional antidepressants primarily act on monoamine neurotransmitter systems:

• SSRIs (fluoxetine, sertraline, escitalopram, etc.): Block serotonin reuptake
• SNRIs (venlafaxine, duloxetine): Block serotonin and norepinephrine reuptake
• NDRIs (bupropion): Block norepinephrine and dopamine reuptake
• TCAs (amitriptyline, nortriptyline): Block multiple monoamine transporters

These drugs improve serotonin, norepinephrine, and/or dopamine signaling but do not directly address glutamatergic or neuroplasticity mechanisms.

Ketamine, by contrast:

• Blocks NMDA glutamate receptors (see key clinical trials for the evidence)
• Triggers rapid BDNF release and synaptogenesis
• Activates AMPA receptors indirectly
• Modulates mTOR signaling
• Generates neuroplastic hydroxynorketamine metabolites

These mechanisms are largely non-overlapping with monoaminergic antidepressants. When both types of drugs are present simultaneously, they may:

1. Address multiple pathophysiological mechanisms simultaneously
2. Produce additive or synergistic antidepressant effects
3. Allow lower doses of each drug while maintaining combined efficacy
4. Enable conventional antidepressants to "consolidate" the neuroplastic gains initiated by ketamine

The FDA Label Requirement

Notably, the FDA requires Spravato to be used in combination with an oral antidepressant — not as monotherapy. This regulatory requirement reflects both the evidence base (all Spravato trials included concurrent antidepressants) and the mechanistic rationale that the combination may be more effective and/or more durable than ketamine alone.

While this requirement is specific to Spravato, the underlying principle — that ketamine augments conventional antidepressants rather than replacing them — applies to ketamine tablet practice broadly.

Research Evidence for Combination Protocols

Ketamine + SSRIs

The most common combination in practice, given that SSRIs are the most widely prescribed antidepressants.

Zarate et al. (NIMH): While not specifically a combination study, many of the landmark ketamine depression trials allowed stable SSRI backgrounds. The antidepressant effects observed were present on top of ongoing SSRI treatment, demonstrating that SSRIs do not block ketamine's antidepressant mechanism.

Murrough et al. (2013): The large NIMH IV ketamine trial that established compelling efficacy data enrolled patients on stable antidepressants (mostly SSRIs and SNRIs). Response rates of 64% were observed — suggesting the combination performs well.

Basic science support: Animal studies have shown additive or synergistic antidepressant effects when SSRIs are combined with ketamine, potentially through SERT (serotonin transporter) blockade enhancing the downstream neuroplastic effects of ketamine's NMDA antagonism.

Ketamine + Lithium

Lithium is a classic augmentation agent for antidepressant-resistant depression, and its combination with ketamine is both biologically interesting and clinically used.

GSK-3β interaction: Both lithium and ketamine inhibit GSK-3β kinase — a signaling molecule involved in neuroplasticity, mood regulation, and the pathophysiology of depression. This overlapping mechanism raises the possibility of synergy.

Caution: Lithium requires careful monitoring, particularly given its narrow therapeutic index. Ketamine can affect fluid balance, which may in turn affect lithium levels. Patients on lithium + ketamine require closer lithium level monitoring.

Clinical use: Some specialized ketamine programs use lithium as the concurrent oral medication specifically for its GSK-3β interaction.

Ketamine + SNRIs

SNRIs (venlafaxine, duloxetine, desvenlafaxine) are widely used in TRD augmentation. Combination with ketamine tablet follows similar principles as SSRIs. One additional consideration: SNRIs' norepinephrine reuptake blockade may increase ketamine's cardiovascular effects slightly (additive sympathomimetic effects), warranting attention to blood pressure monitoring.

Ketamine + Bupropion

Bupropion's dopamine and norepinephrine effects complement ketamine's glutamatergic mechanism. The combination is commonly used in clinical practice. No specific interaction concerns have been identified, though bupropion lowers the seizure threshold — a theoretical concern with ketamine at higher doses (ketamine has proconvulsant effects at very high doses, though this is rarely relevant at oral therapeutic doses).

Ketamine + MAOIs: Significant Caution

MAOIs (monoamine oxidase inhibitors) — phenelzine, tranylcypromine, selegiline — are sometimes used for TRD and have a potentially concerning interaction with ketamine.

Mechanism of concern: MAOIs increase synaptic levels of serotonin, dopamine, and norepinephrine. Ketamine also increases monoamine release through indirect mechanisms. Theoretically, this combination could precipitate serotonin syndrome — a potentially life-threatening condition characterized by agitation, hyperthermia, autonomic instability, and neuromuscular abnormalities.

Clinical reality: Published serious adverse events with the combination are rare, and some clinical programs have used ketamine tablet in patients on MAOIs with careful monitoring. However, the theoretical risk is meaningful, and most experts recommend against combining ketamine with irreversible MAOIs unless benefits clearly outweigh risks and there is specific expertise.

Caution applies to: Phenelzine, tranylcypromine, and isocarboxazid (irreversible MAOIs). Selegiline (at low transdermal doses) may have a somewhat lower risk due to selectivity, but caution still applies.

Ketamine + Atypical Antipsychotics

Atypical antipsychotics (quetiapine, aripiprazole, lurasidone) are commonly used as augmentation agents in TRD and are often on board when ketamine is added.

Pharmacological interactions: Some atypical antipsychotics have significant CYP3A4 interactions (quetiapine is a CYP3A4 substrate; some atypicals inhibit CYP enzymes), which may affect ketamine tablet metabolism. This requires clinical attention but is generally manageable.

Clinical evidence: The Spravato trials included patients on antidepressant + atypical antipsychotic combinations. No unusual safety signals were identified.

The Role of Norketamine in Augmentation

An important consideration in combination therapy is that ketamine tablet generates more norketamine than IV. Norketamine's receptor profile (NMDA antagonism + AMPA potentiation + opioid receptor interactions) may interact with concurrent antidepressants differently than ketamine itself.

Specifically, the emerging research on (2R,6R)-HNK suggests that this metabolite potentiates AMPA receptors — a mechanism that overlaps with some antidepressant effects. The AMPA-potentiating effects of HNK may synergize with the serotonin-mediated plasticity from concurrent SSRI treatment.

Practical Protocol Considerations

For patients adding ketamine tablet to existing antidepressants:

Continue existing antidepressants: Do not stop SSRIs, SNRIs, or other medications when adding ketamine unless specifically directed by the prescriber. Abrupt antidepressant discontinuation causes its own problems.

Monitor for interactions: Review all medications at each prescriber visit with specific attention to CYP3A4 interactions and CNS drug burden.

Assess combined CNS effects: The sedation and cognitive effects of ketamine may be additive with any concurrent CNS-active medications. Starting at lower ketamine tablet doses when other CNS drugs are on board is prudent.

Blood pressure monitoring: More important when ketamine is combined with medications that have their own cardiovascular effects (SNRIs raise blood pressure; some atypical antipsychotics cause orthostatic hypotension).

Duration of combination: How long to continue ketamine alongside conventional antidepressants depends on clinical response, tolerability, and cost. Some patients use ketamine as a time-limited augmentation (3–6 months) to achieve remission, then taper ketamine while maintaining the conventional antidepressant. Others require indefinite combination therapy to sustain response.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches